Mitochondrial delivery of microRNA mimic let-7b to NSCLC cells by PAMAM-based nanoparticles

References

• Ma X, Gong N, Zhong L, et al. Future of nanotherapeutics: targeting the cellular sub-organelles. Biomaterials. 2016;97:10–21.
   PubMed Web of Science ®Google Scholar
• FitzGerald KE, Konduri PC, Vidal C, et al. The Bioenergetic Role of Mitochondria in Lung Cancer. A Global Scientific VisionPrevention, Diagnosis, and Treatment of Lung Cancer. 2017. 165.
   Google Scholar
• Viale A, Corti D, Draetta GF. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015;75(18):3687–3691.
   Web of Science ®Google Scholar
• Giuliani A, Prattichizzo F, Micolucci L, et al. Mitochondrial (Dys) function in inflammaging: do MitomiRs influence the energetic, oxidative, and inflammatory status of senescent cells?. Mediators Inflammation. 2017;2017:1–11.
   Web of Science ®Google Scholar
• Barrey E, Saint-Auret G, Bonnamy B, et al. Pre-microRNA and mature microRNA in human mitochondria. PLoS One. 2011;6(5):e20220.
   PubMed Web of Science ®Google Scholar
• Borralho PM, Rodrigues CMP, Steer CJ. Mitochondrial microRNAs and their potential role in cell function. Curr Pathobiol Rep. 2014;2(3):123–132.
   Google Scholar
• Sripada L, Tomar D, Singh R. Mitochondria: one of the destinations of miRNAs. Mitochondrion. 2012;12(6):593–599.
   PubMed Web of Science ®Google Scholar
• Bian Z, Li L-M, Tang R, et al. Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions. Cell Res. 2010;20(9):1076–1078.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Rüberg S, Girard M, et al. Nuclear outsourcing of RNA interference components to human mitochondria. PLoS One. 2011;6(6):e20746.
   PubMed Web of Science ®Google Scholar
• Sripada L, Tomar D, Prajapati P, et al. Systematic analysis of small RNAs associated with human mitochondria by deep sequencing: detailed analysis of mitochondrial associated miRNA. PLoS One. 2012;7(9):e44873.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7(6):759–764.
   PubMed Web of Science ®Google Scholar
• Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67(16):7713–7722.
   PubMed Web of Science ®Google Scholar
• George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan-a review. J Control Release. 2006;114(1):1–14.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974.
   PubMed Web of Science ®Google Scholar
• Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 2009;71(3):445–462.
   PubMed Web of Science ®Google Scholar
• Eftekhari R B, Maghsoudnia N, Samimi S, et al. Co-Delivery Nanosystems for Cancer Treatment: A Review. PNT. 7(2):90–112. doi:10.2174/2211738507666190321112237.
   Google Scholar
• Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10(1):35–43.
   PubMed Web of Science ®Google Scholar
• Tomalia DA. Dendritic effects: dependency of dendritic nano-periodic property patterns on critical nanoscale design parameters (CNDPs). New J Chem. 2012;36(2):264–281.
   Web of Science ®Google Scholar
• Bielski E, Zhong Q, Mirza H, et al. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations. Int J Pharm. 2017;527(1–2):171–183.
   PubMedGoogle Scholar
• Perez AP, Romero EL, Morilla MJ. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm. 2009;380(1–2):189–200.
   PubMedGoogle Scholar
• Wang J, Dou B, Bao Y. Efficient targeted pDNA/siRNA delivery with folate-low-molecular-weight polyethyleneimine-modified pullulan as non-viral carrier. Mater Sci Eng C Mater Biol Appl. 2014;34:98–109.
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Khalil M, Gurbuz M, et al. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1–7.
   PubMed Web of Science ®Google Scholar
• Bielski ER, Zhong Q, Brown M, et al. Effect of the conjugation density of triphenylphosphonium cation on the mitochondrial targeting of poly(amidoamine) dendrimers. Mol Pharm. 2015;12(8):3043–3053.
   PubMedGoogle Scholar
• Biswas S, Dodwadkar NS, Piroyan A, et al. Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials. 2012;33(18):4773–4782.
   PubMed Web of Science ®Google Scholar
• Han M, Lv Q, Tang XJ, et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release. 2012;163(2):136–144.
   PubMed Web of Science ®Google Scholar
• Lu P, Bruno BJ, Rabenau M, et al. Delivery of drugs and macromolecules to the mitochondria for cancer therapy. J Control Release. 2016;240:38–51.
   PubMed Web of Science ®Google Scholar
• Cavalli LR, Varella-Garcia M, Liang BC. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ. 1997;8(11):1189–1198.
   PubMedGoogle Scholar
• Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006;125(7):1241–1252.
   PubMed Web of Science ®Google Scholar
• Reily C, Mitchell T, Chacko BK, et al. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. 2013;1(1):86–93.
   PubMed Web of Science ®Google Scholar
• Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal. 2011;15(12):3021–3038.
   PubMed Web of Science ®Google Scholar
• Naz S, Wang M, Han Y, et al. Enzyme-responsive mesoporous silica nanoparticles for tumor cells and mitochondria multistage-targeted drug delivery. Int J Nanomedicine. 2019;14:2533–2542.
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhang H, Qin Y, et al. Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria. Drug Dev Ind Pharm. 2018;44(12):2071–2082.
   PubMed Web of Science ®Google Scholar
• Wang K, Qi M, Guo C, et al. Novel dual mitochondrial and CD44 receptor targeting nanoparticles for redox stimuli-triggered release. Nanoscale Res Lett. 2018;13(1):32.
   PubMedGoogle Scholar
• Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm. 2003;252(1–2):263–266.
   PubMed Web of Science ®Google Scholar
• Ciolkowski M, Petersen JF, Ficker M, et al. Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomedicine. 2012;8(6):815–817.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Banerjee S, Gupta U, et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater Today. 2015;18(10):565–572.
   Web of Science ®Google Scholar
• Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401.
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70(18):7027–7030.
   PubMed Web of Science ®Google Scholar
• Duarte FV, Palmeira CM, Rolo AP. The emerging role of MitomiRs in the pathophysiology of human disease. microRNA: Medical Evidence. New York: Springer; 2015. p. 123–154.
   Google Scholar
• Shi L, Middleton J, Jeon Y-J, et al. KRAS induces lung tumorigenesis through microRNAs modulation. Cell Death Dis. 2018;9(2):219.
   PubMedGoogle Scholar
• Wang X, Cao L, Wang Y, et al. Regulation of let-7 and its target oncogenes (Review). Oncol Lett. 2012;3(5):955–960.
   PubMed Web of Science ®Google Scholar
• Wei J, Zhao J, Long M, et al. p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC Cancer. 2010;10(1):632.
   PubMedGoogle Scholar
• Mortenson MM, Schlieman MG, Virudachalam S, et al. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004;54(4):343–353.
   PubMed Web of Science ®Google Scholar
• Chou C-H, Shrestha S, Yang C-D, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296–D302.
   PubMed Web of Science ®Google Scholar